Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

VIDAZA prolongs survival in AML patients

The Myelodysplastic Syndromes (MDS) Foundation says a study published this week in the Journal of Clinical Oncology concludes VIDAZA (azacitidine) “prolongs survival and is well tolerated” in patients with acute myeloid leukemia (AML) - an aggressive form of leukemia that in many cases progresses from MDS.

3 Feb 2010

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.

2 Feb 2010

Safer bone marrow transplants

If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.

2 Feb 2010

GMC designated as NMDP collection site to collect bone marrow from willing donors

Geisinger Medical Center (GMC) was recently designated a National Marrow Donation Program (NMDP) collection site, becoming the only site in the region to collect bone marrow or blood stem cells from willing donors.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.

29 Jan 2010

ASH offers hematologists a new resource for earning CME credits

The American Society of Hematology (ASH) now offers physicians who diagnose and treat blood disorders a new resource for earning continuing medical education (CME) credits while staying abreast of the latest clinical strategies in the rapidly changing field of hematology.

29 Jan 2010

How to recognize heart attack symptoms in younger women

The risk for heart-related death is increasing in young adults ages 35 to 54, and the numbers are even more alarming for younger women. It is the number-one cause of death for both men and women in the United States, yet every year since 1984 more women have died of cardiovascular health problems than men, according to the American Heart Association.

29 Jan 2010

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

New research in the FASEB Journal shows that bone marrow cells fuse to different types of cells, including embryonic stem cells, creating new hybrids that may evade immune rejection

29 Jan 2010

Adipose tissue, a promising new source of HSPCs

Bone marrow is a leading source of adult stem cells, which are increasingly used for research and therapeutic interventions, but extracting the cells is an arduous and often painful process. Now, researchers have found evidence that fat tissue, known as adipose tissue, may be a promising new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells (HSPCs), according to astudy prepublished online in Blood, the official journal of the American Society of Hematology.

28 Jan 2010

Good bacteria may help counteract negative effects of antibiotics in humans

Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why.

27 Jan 2010

Blood system offers a potential therapeutic avenue for age-related stem cell dysfunction

As you age, your blood ages. Deep in your bone marrow, blood stem cells keep churning out your blood cells, but the mix of blood cell types goes awry, making you more prone to disease.

27 Jan 2010

New research project aims at understanding the genetic origins of childhood cancers

St. Jude Children's Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world's deadliest childhood cancers.

27 Jan 2010

Discovery challenges understanding of blood cell development

University of Utah researchers led an international team of scientists that is the first to report on the previously undescribed ability of platelets to reproduce themselves in the circulation. Their revolutionary findings were published online Jan. 19, 2010, in the journal Blood.

27 Jan 2010

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.

27 Jan 2010

Promising results in mice could prevent fatal iron buildup in humans

A new study shows that a protein found in blood alleviates anemia, a condition in which the body's tissues don't get enough oxygen from the blood. In this animal study, injections of the protein, known as transferrin, also protected against potentially fatal iron overload in mice with thalassemia, a type of inherited anemia that affects millions of people worldwide.

27 Jan 2010

Bone Marrow News and Research

Further Reading

VIDAZA prolongs survival in AML patients

FDA accepts Teva Pharmaceutical Industries' BLA for XM02 G-CSF

Cytheris broadens patent protection for recombinant human interleukin-7

FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Safer bone marrow transplants

GMC designated as NMDP collection site to collect bone marrow from willing donors

Researchers design bioactive nanomaterial that promotes cartilage growth

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Positive Phase 2 trial results of Keryx Biopharmaceuticals' KRX-0401 announced

ASH offers hematologists a new resource for earning CME credits

How to recognize heart attack symptoms in younger women

New research raises hopes that immune rejection of embryonic stem cell therapies can be avoided without drugs

Adipose tissue, a promising new source of HSPCs

Good bacteria may help counteract negative effects of antibiotics in humans

Blood system offers a potential therapeutic avenue for age-related stem cell dysfunction

New research project aims at understanding the genetic origins of childhood cancers

Discovery challenges understanding of blood cell development

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Promising results in mice could prevent fatal iron buildup in humans

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News